Taysha Gene Therapies

TSHA

Market cap $1.59B

5.79 USD

+0.03

0.52%

At close Updated Dec 12, 4:00 PM EST

Pre-market

After hours

5.80

+0.01

0.17%

1 day

0.52%

5 days

13.09%

1 month

32.8%

3 months

88.6%

6 months

118.49%

Year to date

212.97%

1 year

157.33%

5 years

-72.62%

10 years

-75.94%

About: Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Employees: 73

Healthcare Biotechnology